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Overexpression of fibroblast growth factors (FGFs) has been implicated in prostate carcinogenesis. FGFs function via their high-affinity
interactions with receptor tyrosine kinases, FGFR1–4. Expression of FGFR1 and FGFR2 in prostate cancer (CaP) was not found to be
associated with clinical parameters. In this report, we further investigated for abnormal FGFR expression in prostate cancer and
explore their significance as a potential target for therapy. The expression levels of FGFR3 and FGFR4 in CaP were examined and
corroborated to clinical parameters. FGFR3 immunoreactivity in benign prostatic hyperplasia (BPH) and CaP (n¼26 and 57,
respectively) had similar intensity and pattern. Overall, FGFR4 expression was significantly upregulated in CaP when compared to
BPH. A significant positive correlation between FGFR4 expression and Gleason score was noted: Gleason score 7–10 tumours
compared to BPH (Po0.0001, Fisher’s exact test), Gleason score 4–6 tumours compared to BPH (Po0.0004), and Gleason 7–10
compared to Gleason 4–6 tumours (Po0.005). FGFR4 overexpression was associated with an unfavourable outcome with
decreased disease-specific survival (Po0.04, log rank test). FGF-induced signalling is targeted using soluble FGF receptor (sFGFR),
potent inhibitor of FGFR function. We have previously shown that sFGFR expression via a replication-deficient adenoviral vector
(AdlllcRl) suppresses in vitro FGF-induced signalling and function in human CaP DU145 cells. We tested the significance of inhibiting
FGF function along with conventional therapeutic modalities in CaP, and confirmed synergistic effects on in vitro cell growth
(proliferation and colony formation) by combining sFGFR expression and treatment with either Paclitaxel (Taxol
s)o rg-irradiation. In
summary, our data support the model of FGF system as valid target for therapy in CaP.
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Prostate cancer is the commonest cancer in men and the second
commonest cause of cancer-related death in men, and its incidence
is increasing (Woolf, 1995; Boyle et al, 1996). Prostate cancer is an
enigmatic disease. It is histologically present in 80% of men over
the age of 80 years, but will only clinically manifest itself in about
10%. Increasing use of serum measurement of prostate-specific
antigen is facilitating early diagnosis of prostate cancer. There are
currently limited prognostic markers that may allow patients
found to have early prostate cancer to be stratified into different
management plans. Hence, new methods of predicting disease
progression are urgently needed.
Abnormal expression of peptide growth factors and their high-
affinity receptor tyrosine kinases are important in the development
and progression of prostate cancer. These mitogens enhance
tumour proliferation and invasion while inhibiting apoptosis.
Several peptide growth factors have been implicated in prostate
cancer development and progression, including insulin-like
growth factors, epidermal growth factor and members of the
fibroblast growth factors (Byrne et al, 1996; Tennant et al, 1996;
Dorkin et al, 1999a).
The family of fibroblast growth factors (FGFs) and their
receptors (FGFRs) are important in the prostate organogenesis
as well as the pathogenesis of prostate cancer (Cunha et al, 1987;
Leung et al, 1996; Ittmann and Mansukhani, 1997; Dorkin et al,
1999b). Fibroblast growth factors make up a large family of 23
related polypeptides with highly conserved amino-acid sequences,
sharing 13–71% sequence homology, ranging from 17 to 34kDa in
molecular weight (Ornitz and Itoh, 2001; Yamashita et al, 2000).
The FGF family interacts directly with heparin and heparin-like
glycosaminoglycans. This provides essential functions in stabilis-
ing FGFs and facilitating effective interaction between FGF and
FGFR (Mansukhani et al, 1992; Roghani et al, 1994).
FGFRs are transmembrane receptor tyrosine kinases. Upon
ligand binding, FGFRs undergo dimerisation and transphosphory-
lation at the intracellular kinase domain. Four FGFR genes have
been cloned in humans and they share a 55–72% sequence
homology (Jaye et al, 1992; Powers et al, 2000). FGFR proteins are
characterised by three immunoglobulin (Ig)-like domains (desig-
nated loops I, II, and III) within the extracellular region, a single
transmembrane region and a split cytoplasmic tyrosine kinase
domain. Only loops II and III are required for FGF binding, while
the C-terminal portion of loop III determines the ligand specificity.
Different receptor isoforms arise due to alternate splicing of exons
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scoding for Ig loop III (Ornitz et al, 1996). For example, alternative
splicing of FGFRl results in isoforms designated FGFRlIIIb and
FGFRlIIIc, which have differential FGF binding characteristics.
FGFRlIIIb binds efficiently to aFGF, FGF3 and FGF 10, while FGFRl
Ilk binds to aFGF, bFGF, FGF4, FGF6, FGF8 and FGF9 (Ornitz et al,
1996). FGFRl-3 demonstrate both IIIb and IIIc splice variant
isoforms, but FGFR4 is unique and has no IIIb splice variant, being
expressed as the IIIc isoform only (Johnson et al, 1991; Vainikka
et al, 1992; Chellaiah et al, 1994).
Soluble FGFR, containing the extracellular ligand-binding
domain of the native FGFR, is secreted and without a tyrosine
kinase domain. A number of studies have assessed the inhibitory
effect of the tyrosine kinase-deficient growth factor receptors
(FGFR and vascular endothelial growth factor receptor (VEGFR)
(Celli et al, 1998; Ozen et al, 2001; Mahasreshti et al, 2001; Ogawa
et al, 2002; Becker et al, 2002). The main characteristics of these
soluble growth factor receptors include the ability to bind ligand in
the extracellular space, thus ‘mopping up’ the ligands preventing
them from binding to the native full-length receptors, and to
dimerise with the native receptors forming inactive homo- or
hetero- dimers, thus blocking ligand-induced cellular signalling
and function. Celli et al, using a soluble FGFR 2 construct,
demonstrated inhibition of FGF-induced signalling, resulting in
lethal defects in organogenesis. The soluble form of the FGFR was
found to be more potent than the membrane-bound form (Celli
et al, 1998). Using adenoviral-mediated soluble FGFRlIIIc expres-
sion, work from our laboratory have previously demonstrated
significant suppression of FGF-induced signalling and function
(proliferation and invasion) in human prostate cancer DU145 cells
(Gowardhan et al, 2004). The efficacy of such an approach remains
to be tested against chemotherapy and radiotherapy, modalities of
cancer treatment in current clinical practice.
FGFR1 is overexpressed in prostate cancer, and FGFR2 has been
detected in both prostate cancer and benign prostatic hyperplasia
(Leung et al, 1997; Giri et al, 1999). However, neither FGFR1 nor
FGFR2 expression in prostate cancer was noted to have any
significant correlation to clinical parameters including tumour
grade, stage, and outcome on disease survival. The objectives of
this study were two-fold. First, we examined for abnormal
expression of FGFR3 and FGFR4 in clinical prostate cancer
specimens. Second, the novel approach of targeting the FGF
system in combination with chemotherapy (paclitaxel) or radia-
tion therapy (g-irradiation) was tested using an in vitro DU145
prostate cancer cell model.
MATERIALS AND METHODS
Patients and samples
Archival prostate specimens from cases of newly diagnosed
prostate cancer were obtained from transurethral resection of the
prostate gland (TURP). The specimens were formalin fixed and
paraffin embedded. Sections were prepared and mounted on
APES-coated slides. A total of 57 cases of prostate cancer and 26
cases of benign prostate hyperplasia were selected. The age range
of the cancer group was 56–86 years (mean age 71 years) at the
time of diagnosis. Bone scans were performed in 50 of these 57
patients. In total, 21 of the bone scans were positive, signifying the
presence of bony metastases. A summary of the relevant
demographic data is presented in Table 1.
Immunohistochemistry
Fibroblast growth factor receptors 3 and 4 protein expression
levels were examined using immunohistochemistry. Prior to
commencing staining of the prostate specimens, the use of FGFR3-
and FGFR4-specific antibodies were optimised on serial prostate
sections to demonstrate clean and reproducible signals. The
antibodies were also tested by Western blotting to show specific
band of the correct molecular weight for each receptor (data not
shown). The slides were dewaxed in xylene prior to rehydration in
100, 70 and 50% ethanol and finally water. Endogenous peroxidase
activity was blocked with 30% hydrogen peroxide diluted 1:60 in
methanol, then placed in water prior to antigen retrieval using
pressure cooking in a 0.01 M citrate buffer (pH¼6.0) for 6min.
The slides were then placed in phosphate-buffered saline (PBS),
before blocking with 10% swine serum in PBS for 20min. The
primary antibodies were then applied at 1:200 (5mgml
 1) for
FGFR3 and 1:200 (5mgml
 1) for FGFR4 and incubated at 41C
overnight, (rabbit anti-FGFR3 and FGFR4 polyclonal IgG; Santa
Cruz, USA). Sections were also incubated in PBS alone as a
negative control. The slides were then washed in PBS before
incubation with the secondary biotinylated swine anti-rabbit IgG
antibody (Dako, UK) diluted at 1:250 in PBS for 30min at room
temperature. Following further washings in PBS, visualisation of
immunoreactivity was performed using Vectastain Avidin Biotin
Complex Kit (Vector Laboratories, UK), according to the
manufacturer’s instructions. Finally, the slides were treated with
DAB (3030-diaminobenzidetetrahydrochloride), and then counter-
stained with Harris haematoxylin, before dehydration with graded
ethanol and xylene prior to being mounted with cover slide.
Scoring of slide sections
The slides were viewed by light microscopy and scored for staining
intensity of FGFR3 and FGFR4. Two independent observers (DAD
and MEM) scored all sections, with no knowledge of the clinical
parameters for each section at the time of scoring. The scoring was
semiquantitative looking for presence and intensity of staining.
FGFR3 and FGFR4 immunoreactivity was considered positive if
more than 25% of the section was stained. Intensity of the staining
was graded as negative (0), weak (1), moderate (2), and strong (3)
as previously published (Armes et al, 1999; Bouras et al, 2001).
Cells, cell culture, and treatment with paclitaxel or c-
irradiation
Cultured cells were maintained in growth medium (RPMI 1640
(Gibco BRL, Invirrogen, Paisley, UK), containing HEPES buffer
(25mM) and L-glutamine (20mM)), supplemented with 10% heat-
inactivated fetal calf serum (Sigma-Aldrich, Dorset, UK),
100Uml
 1 of penicillin, and 100mgml
 1 of streptomycin (Gibco
BRL); this was referred to as full medium. The androgen-
unresponsive human prostate carcinoma DU145 cell line was
Table 1 Clinical details
Total
number
(n¼38)
a
Metastases at
diagnosis
b
Mean
serum
PSA
PSA
range
No. with
PSA data
(n¼21)
c
Stage
Tl 12 1/12 17.1 2.7–45 5
T2 11 6/11 271.2 3.6–1436 6
T3 9 4/6 333.6 5.7–2000 7
T4 6 5/6 79.0 3.6–136 3
Gleason score (n¼57)
2–6 9 1/9 67.2 2.7–154 3
7 7 1/6 16.7 3.6–26.9 4
8–10 41 19/35 286.9 3.6–2000 14
aT stage at diagnosis was not available for 19 of the prostate carcinoma cases.
bNot all
cases had a bone scan prior to or shortly after the time of surgery.
cPSA data were
unavailable for 36 cases at the time of diagnosis. PSA value is in nanograms per
millilitre (ngml
 1).
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spurchased from the American Type Culture Collection (ATCC,
Rockville, MD, USA). The 293T cell line (El-transformed human
embryonic kidney cells) was a kind gift from Professor A
Sharrocks (Manchester University, UK) and used as a packaging
cell line for adenoviruses. Paclitaxel (Taxol
s) (Sigma-Aldrich,
Dorset, UK) was reconstituted to a final concentration of
lmmolml
 1. g-Irradiation was delivered at a dose of
3.26Gymin
 1.
Preparation of the soluble FGFR1 gene construct
The details of the preparation of the soluble FGFR1 gene construct
have been previously described (Li et al, 2002). Briefly, the soluble
FGFR1 gene was cloned using polymerase chain reaction (PCR)
and incorporated into the adenoviral AdTrack vector, which is a
shuttle vector containing a GFP expression cassette and two
cytomegaloviral promoter regions. The recombinant AdTrack
vector was cotransformed with the adenoviral backbone vector
AdEasy to yield the recombinant adenoviral construct (AdIIIcRl).
The construct was amplified by successive transfections/infections
in HEK293T cells and the viral particles harvested by five cycles of
freeze–thawing. The viruses were purified using CsCl and titrated
using the tissue culture infectious dose 50 (TCID50) method.
Similarly, control empty adenoviruses without the soluble FGFR1
gene were constructed (AdE).
Proliferation assay
A total of 3000 DU145 cells per well were seeded out in 96-well
plates and allowed to grow for 24h in full medium. Typically, the
cells were 70% confluent at 24h, and the medium was replaced
with a 10ml of full medium with or without adenovirus stock
(AdIIIcRl or AdE; 100 viral particles per cell (p.p.c.) respectively).
Plates were then incubated for 3h at 371C, 5% CO2 with gentle
shaking to allow maximum contact of virus with all cells. The cells
were maintained in full medium with Paclitaxel at doses of 0, 2.5, 5,
7.5 and 10nmolml
 1, for 5 days at 371C, 5% CO2. At this point,
10ml of (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-
1,3-benzene disulphonate) (WST-1, Roche, Welwyn Garden City,
Hertfordshire, UK) was added to each well and incubated at 371C,
5% CO2 for 3h. The plate were read using an ELISA reader at a
wavelength of 450nm. As a further control, we used cells treated
with the same doses of paclitaxel but without adenoviruses.
In a separate experiment, 3 10
4 DU145 cells were resuspended
in 1ml of full media per sterile universal container. They were then
exposed to g-irradiation at doses of 0, 2,4, 6, 8 and 10Gy. The cells
were then seeded out in a 96-well plate at a concentration of 3000
cells per well in 100ml of full medium. After 24h, the medium was
removed and was replaced with a 10ml of full medium with or
without adenovirus stock (AdIIIcRl or AdE; 100 viral p.p.c.,
respectively). Plates were then incubated for 3h at 371C, 5% CO2
after which 90ml of full media were added to make up a final
volume of 100ml. The plates were then incubated for 5 days. At this
point, 10ml of (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetra-
zolio]-1,3-benzene disulphonate) (WST-1, Roche) was added to
each well and incubated at 371C, 5% CO2 for 3h. The plate was
read using an ELISA reader at a wavelength of 450nm. As a further
control, we used cells treated with the same doses of g-irradiation
but without adenoviruses. Both experiments were performed in
quadruplet and repeated three times.
Colony-forming assay
In total, 5000 DU145 cells were seeded out in T25 flasks in 6ml of
full media. After 24h, the medium was removed and adenoviral
stock at a dose of 100viral p.p.c. (AdlllcRl or AdE) in 1ml of full
media was added and the flasks incubated for 3h at 371C, 5% CO2
on a shaker. Amounts of 5ml of full medium containing paclitaxel
at doses of 0, 1, 2.5, 5, 7.5 and 10 was then added to make up a final
volume of 6ml. The plates were then incubated for 14 days at 371C,
5% CO2 without changing the media. As a further control, cells
treated with paclitaxel but without adenoviruses were used. After
14 days, the medium was removed; cells washed gently with sterile
PBS, and fixed with methanol:acetic acid (3:1) for 30min at room
temperature. The fixing reagent was removed and 0.4% Methylene
blue added to stain the colonies for 30min. The methylene blue
was removed and colonies washed gently with water to remove
excess stain. The colonies were then counted. The experiment was
repeated three times.
In a separate experiment, 5000 DU145 cells were resuspended in
1ml of full medium in sterile universal containers. They were then
exposed to 0, 2. 4, 6, 8 and 10Gy of g-irradiation. The cells were
then seeded out in T25 flasks and incubated for 24h at 371C, 5%
CO2. After 24h, the medium was removed and replaced with
adenoviral stock (AdlllcRl or AdE) at a dose of 100 viral p.p.c. in
1ml of full medium. The plates were incubated for 3h at 371C, 5%
CO2 with gentle shaking. Amounts of 5ml of full medium was then
added to make up a final volume of 6ml. The plates were then
incubated for 14 days at 371C, 5% CO2 without changing the
medium. As a further control, cells exposed to g-irradiation but
without adenoviruses were used. After 14 days, the medium was
removed; cells washed gently with sterile PBS, and the cells fixed
with methanol:acetic acid (3:1) for 30min at room temperature.
The fixing reagent was removed and 0.4% methylene blue added to
stain the colonies for 30min. The methylene blue was removed and
colonies washed gently with water to remove excess stain. The
colonies were then counted. The experiment was repeated three
times.
Statistical analysis
Immunoreactivity of FGFR3 and FGFR4 in prostate carcinoma and
BPH was analysed using Fisher’s exact test of probability. To
analyse patient survival compared to FGFR expression, Kaplan–
Meier survival curves were plotted and the difference in survival
between different groups assessed using the log rank test. To
perform these tests the statistical package Arcus Quickstat
(Biomedical Version 1.1) was used.
Differences in mean values of absorbance on WST-1 assay and
number of colonies in the colony-forming assay were evaluated
using the Student’s t-test for unpaired data. A probability value of
less than 0.05 was taken to indicate statistical significance.
RESULTS
FGFR3 expression is not upregulated in prostate cancer
Immunoreactivity for FGFR3 was observed in majority (495%) of
the cases examined, both specimens from prostate carcinoma and
BPH. The staining pattern was uniform throughout the epithelium
with moderate to strong staining intensity. In contrast, the stroma
expressed FGFR3 at low levels. Epithelial staining was observed to
be both cytoplasmic and nuclear, with moderate immunoreactivity
in the cytoplasm and strong signals in the nucleus.
The intensity of immunoreactivity was compared between the
BPH and prostate carcinoma specimens. No difference in overall
expression of FGFR3 was found between benign and malignant
prostate epithelium (Figure 1). The relative cytoplasmic and
nuclear FGFR3 signals in benign and malignant prostate epithe-
lium were similar.
FGFR4 expression in human prostate cancer
FGFR4 immunoreactivity was seen in both benign and malignant
prostate sections. Signals observed in the stroma were scanty and
at low intensity. The malignant epithelium showed uniform
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smoderate to strong immunoreactivity for FGFR4. FGFR4 staining
was entirely cytoplasmic, with no nuclear signals. In some sections,
there was also convincing membranous staining in keeping with a
transmembranous localisation of FGFR4 (Figure 2).
FGFR4 immunoreactivity was compared between BPH and
various grades of prostate cancer. The staining intensity was
increased in cancer compared to BPH. The prostate cancer
specimens were divided into low to moderate- and high-grade
disease, representing Gleason sum scores of o7 and 7–10,
respectively. The scores for each group were analysed using
Fisher’s exact test. Both low to moderate-grade and high-grade
tumours had significantly higher expression of FGFR4 than BPH
(Po0.0004 and o0.0000l, respectively). High-grade prostate
cancer also had significantly higher expression of FGFR4 protein
than moderate-grade prostate cancer (Po0.005) (Figure 3).
Increased FGFR4 immunoreactivity was significantly associated
with decreased patient survival. In the cancer group, 51 patients
had informative survival data. FGFR4 overexpression was asso-
ciated with less favourable disease-specific survival (Po0.006,
Figure 4A). In this group, patients with low to moderate staining
for FGFR4 had a mean survival time of 64.6 months, compared to
45.5 months for patients with prostate cancer expressing high
levels of FGFR4. Among patients with high-grade disease (Gleason
score 8–10), high levels of FGFR4 expression was weakly
associated with decreased survival time (Po0.04, Figure 4B).
Patients with high-grade prostate cancer and low to moderate
staining had a mean survival of 54.4 months compared to 45.5
months for people with high FGFR4 expression in high-grade
Figure 1 Moderate levels of FGFR3 expression are present in both BPH
and prostate cancer: (A) BPH, (B) a case of high-grade prostate cancer.
FGFR3 immunoreactivity is predominantly epithelial, with only weak
stromal signals. FGFR3 expression in the prostate epithelium exhibits a
combination of nuclear and cytoplasmic localisation.
Figure 2 (A) FGFR4 immunoreactivity in a Gleason 8 prostate cancer
specimen, showing moderate to strong FGFR4 immunoreactivity. The
staining is predominantly epithelial and within the epithelium, there is no
nuclear expression of FGFR4. There appears to be increased staining at the
cell membrane, in keeping with the transmembranous nature of the FGFR4.
(B) Comparison of FGFR4 staining in a benign gland next to an area of
prostate cancer (Gleason 9), on the same tissue section. This figure shows
increased FGFR4 expression in the malignant epithelium, in contrast to the
adjacent benign prostate epithelium with no detectable signals.
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Figure 3 Graph showing the different staining intensities for FGFR4,
exhibited between benign prostate and moderate/high-grade prostate
cancer. Moderate-grade cancer had significantly higher expression of
FGFR4 compared to BPH (Po0.0004), as did high-grade cancer
(Po0.00001). Increased expression of FGFR4 was also shown when
comparing moderate to high-grade cancers (Po0.005).
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sprostate cancer. FGFR4 expression was not noted to be associated
with tumour stage, serum PSA or the presence of bony metastases.
Synergistic effects of combined treatment on in vitro
proliferation
AdIIIcRl used on its own caused a suppression of proliferation by
30% in full medium compared to untreated controls. Paclitaxel
when used alone caused a suppression of only 1% at a dose of
2.5nmolml
 1 compared to untreated controls. When the two were
combined the suppression in proliferation was 45% (P¼0.005)
compared to untreated controls. This synergism was noted
throughout the dose range of paclitaxel with a suppression of
63% at 10nmolml
 1 compared to 49% for paclitaxel alone at
10nmolml
 1 (P¼0.049) (Figure 5A). Overall, IC50 for Paclitaxel
was reduced from 10nmolml
 1 (alone) to 2.5nmolml
 1 (com-
bined with soluble FGFR expression).
Similarly, for g-irradiation alone treated cells, the suppression in
proliferation was 8% at a dose of 2Gy compared to untreated cells.
The combination of AdIIIcRl and g-irradiation brought about a
suppression of 45% compared to untreated cells (P¼0.0003). As
with paclitaxel, this suggested a synergism that existed throughout
the dose range. At a higher dose of 10Gy, the combined treatment
suppressed proliferation by 55% as compared to 39% for 10Gy of
g-irradiation alone (P¼0.004) (Figure 5B). With g-irradiation the
IC50 was reduced from 10Gy (single agent) to 8Gy (combined).
Synergistic effects of combined treatment on in vitro
colony formation
AdIIIcRl when used alone caused a suppression of colony
formation by 43% compared to untreated controls. Paclitaxel used
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Figure 4 FGFR4 expression compared to patient survival. (A) Kaplan–
Meier plot comparing survival in patients with high levels of FGFR4
expression compared to patients with low to moderate staining for FGFR4.
Data from all patients with prostate cancer, moderate and high-grade
cancer, was included in this plot. Patients with high expression of FGFR4
had a decreased disease-specific survival time than patients with low to
moderate FGFR4 expression (Po0.0006. log rank test). (B) Kaplan–Meier
plot comparing survival in patients with high Gleason sum score tumours.
Patients with high expression of FGFR4 in this group also had a decreased
survival time compared to low to moderate FGFR4 expression (Po0.036,
log rank test).
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Figure 5 Combination treatment on proliferation of DU145 cells. (A)
soluble FGFRþpaclitaxel: Graph showing a suppression of proliferation by
1% by paclitaxel when used alone at a dose of 2.5nmolml
 1 as compared
to a suppression of 45% when used in combination with sFGFR (P¼0.005).
The synergism of the combined treatment is present throughout the dose
range (AdIIIcRl¼recombinant adenovirus with soluble FGFRl gene;
AdE¼empty adenovirus). Even at a dose of 10nmolml
 1 the suppression
by the combination is significant (P¼0.049). (B) soluble FGFRþg-
irradiation: Graph showing a suppression of proliferation by 8% by g-
irradiation when used alone at a dose of 2Gy as compared to 45% when
used in combination with soluble FGFR (P¼0.0003). The synergism
of the combined treatment is present throughout the dose range
(AdIIIcRl¼adenovirus with soluble FGFRl gene; AdE¼empty adenovirus).
At a dose of 10Gy the suppression continues to be more significant than
single therapy (P¼0.004).
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salone at a paclitaxel dose of 1nmolml
 1 caused suppression in
colony formation by 40% as compared to untreated controls.
When the two treatments were combined, the suppression was
99% at a dose of 1nmolml
 1 (P¼0.0007). With paclitaxel alone,
the colony formation was completely suppressed by a dose of
5nmolml
 1, whereas with the combination complete suppression
was noted at a dose of 2.5nmolml
 1) (Figure 6A). Furthermore,
the IC50 of paclitaxel for colony formation was reduced from 1.25
to 0.5nmolml
 1. This suggested a potent synergism between the
two treatment modalities.
When g-irradiation was used alone, the suppression in colony
formation was 13% as compared to untreated controls. When used
in combination with AdIIIcR1, the suppression was 50% as
compared to untreated controls (P¼0.0001). This synergistic
effect continued with the increasing dose of g-irradiation. At a dose
of 6Gy, the combined treatment resulted in suppression of colony
formation by 99% compared to untreated controls while g-
irradiation used alone at 6Gy caused a suppression by 85%
(P¼0.003). By a dose of 8Gy, both g-irradiation used alone and
the combination treatment caused a complete suppression in
colony formation. With g-irradiation the IC50 for colony forma-
tion was reduced from 5 to 2Gy) (Figure 6B).
DISCUSSION
Overexpression of multiple FGFs (namely aFGF/FGFl, bFGF/FGF2,
FGF6 and FGF8) has been identified in prostate cancer (Leung et al,
1996; Ittmann and Mansukhani, 1997; Dorkin et al, 1999b;
Ropiquet et al, 2000). FGF8 appeared to be particularly important
as paracrine and autocrine factors in prostate cancer (Leung et al,
1996, 1997). FGF8 expression was significantly associated with
tumour grade and stage, and was a predictor of disease-specific
survival in patients followed up for over 10 years (Dorkin et al,
1999a). Of the four FGFRs, expression of FGFR1 and FGFR2 has
been examined in resected prostate cancer specimens. They both
appeared to be expressed in prostate cancer; however, a significant
correlation between their expression and clinicopathologic para-
meters has not been observed.
In this study, we have examined the levels of expression of
FGFR3 and FGFR4 proteins in resected prostate specimens. We
showed that FGFR3 is expressed in the majority of BPH and
prostate cancer. The expression pattern was mainly epithelial with
predominant nuclear signals in both BPH and malignant prostate.
The FGFR3 is a transmembranous receptor but nuclear expression
has previously been described. Several FGFs and FGFR1 and
FGFR3 have been shown to be present within the cell nucleus (Feng
et al, 1996; Kilkenny and Hill, 1996; Stachowiak et al, 1997). The
presence of FGF1 in the nucleus is necessary for maximal
mitogenic response (Mehta et al, 1998). FGFR1 has been shown
to adopt a perinuclear location on ligand activation and also
associates with nuclear matrix and nucleoplasm upon FGF2
induction (Prudovsky et al, 1994; Maher, 1996; Stachowiak et al,
1996).
FGFR3 binds to multiple FGFs known to be upregulated in
human prostate cancer (FGF1, FGF2 and FGF8), and is potentially
important in prostate cancer. However, we did not observe any
significant change in the levels of FGFR3 expression between BPH
and prostate cancer. A more subtle shift in FGFR3 expression from
the cytoplasm to the nucleus, which has been observed in breast
cancer, is not present in prostate cancer (Zammit et al, 2001).
FGFR3 has previously been shown to be the dominant FGFR in
prostate epithelium (Ittmann and Mansukhani, 1997). Hence, we
conclude that there is no significant change in the overall
expression and localisation of the FGFR3 in human prostate
cancer. It would therefore seem unlikely that FGFR3 plays a key
role in prostate carcinogenesis.
Abnormal expression of members of the family of FGF and
receptor represents an appealing target for therapy. Besides FGFR
expression analysis, we describe synergistic effects of combining
soluble FGFR gene therapy with either paclitaxel or g-irradiation
on in vitro growth of DU145 prostate cancer cells. Proliferation
was suppressed by 30, 1 and 8%, respectively, by soluble FGFR (at
100 viral particles per cell (data not shown)). paclitaxel (at
2.5nmolml
 1) and g-irradiation (at 2Gy) when used alone.
Proliferation was suppressed by 45% with the combined treatment
of soluble FGFRþpaclitaxel or sFGFRþg-irradiation (P¼0.005
and 0.0003, respectively) with paclitaxel and g-irradiation used at
the lowest dose. We further evaluated the synergism in a colony-
forming assay using DU145 cells. With single treatment with
soluble FGFR (100 viral particles per cell (data not shown)),
paclitaxel (1nmolml
 1) and g-irradiation (2Gy), suppression in
colony formation was 43, 40 and 13%, respectively. When the
treatments were combined, the suppression was 99 and 50%,
0
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Figure 6 Combination treatment on colony formation of DU145 cells.
(A) soluble FGFRþpaclitaxel: Graph showing a suppression of proliferation
by 40% by paclitaxel when used alone at a dose of 1nmolml
 1 as
compared to 99% when combined with soluble FGFR (P¼0.0007). There
was a complete suppression in colony formation with a dose of
2.5nmolml
 1 when the two treatments were used in combination
(AdIIIcRl¼recombinant adenovirus with soluble FGFRl gene; AdE¼empty
adenovirus). (B) soluble FGFRþg-irradiation: Graph showing a suppression
of colony formation by 13% when g-irradiation is used alone as compared
to 50% when combined with soluble FGFR (P¼0.0001). There was a near-
complete suppression in colony formation with the combined treatment
with a dose of 6Gy of g-irradiation (P¼0.003) (AdIIIcRl¼recombinant
adenovirus with soluble FGFRl gene; AdE¼empty adenovirus).
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 1 of
paclitaxel and 2Gy of g-irradiation. The combined treatment
caused a near-complete suppression of colony formation at a lower
dose than the individual treatments. Hence, the suppression of
FGFR function along with either chemotherapy or radiation
therapy may potentially reduce the dose of chemotherapy or
radiotherapy required to achieve therapeutic success.
Adenoviral-mediated transgene delivery has been combined
with both chemotherapy and radiotherapy in a number of studies
and have been shown to be synergistic, either as a sensitizing agent
or indeed as a means of enhancing transgene expression, both of
which are useful in the treatment of cancers (Zeng et al, 1997;
Seidman et al, 2001; Li et al, 2002). The combination of the two
agents is thought to be beneficial in a number of ways, one of
which is to reduce the dose of either the chemotherapeutic
agent or of radiotherapy. This will, undoubtedly, be of benefit in
reducing toxicity to patients. It is also known that ionising
radiation improves transfection/transduction efficiency and
transgene integration (Zeng et al, 1997). Gene therapy and
radiation therapy target best at different parts of the cell cycle,
that is, gene therapy requires the ‘S’ phase of the cell cycle while
‘M’ and ‘G2’ phases are most radiosensitive (Simons and Marshall,
1998). Phosphorylated prodrugs such as ganciclovir, acyclovir or
valacyclovir are incorporated into the newly synthesised DNA
causing termination of DNA synthesis and, thus, cell death.
This may increase the DNA susceptibility to radiation damage.
Also, by incorporation into the DNA, phosphorylated prodrugs
may interfere with repair of radiation-induced DNA damage.
It is thought that radiation may also enhance the ‘bystander effect’
of gene therapy. This maybe due to the release of products from
the radiation-damaged cells and the efficient uptake and
presentation of tumour antigens by immune effector cells
attracting immunocytes and mediating an antitumour response
(Teh et al, 2002).
In summary, we presented evidence for clinical significant
FGFR4 overexpression in prostate cancer, and further validated the
potential of targeting the FGFR system for treatment in conjunc-
tion with current available modalities.
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